NCT02301624 - Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

November 12, 2014

Primary Completion Date

January 15, 2019

Study Completion Date

January 15, 2019

Conditions

Refractory Generalized Myasthenia Gravis

Interventions

BIOLOGICAL

Eculizumab

Intravenous administration of eculizumab.

DRUG

Placebo

Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.

Trial Locations (60)

27599

Chapel Hill

27710

Durham

28207

Charlotte

32209

Jacksonville

33136

Miami

33612

Tampa

35233

Birmingham

43210

Columbus

46202

Indianapolis

52242

Iowa City

62702

Springfield

66160

Kansas City

78229

San Antonio

89145

Las Vegas

90033

Los Angeles

92868

Orange

94115

San Francisco

94304

Palo Alto

97239

Portland

98195

Seattle

06519

New Haven

21201-1595

Baltimore

21287-0876

Baltimore

02115

Boston

01805

Burlington

05401

Burlington

Unknown

Buenos Aires

Edegem

Ghent

Leuven

São Paulo

Edmonton

Ostrava - Poruba

Prague

Arhus C

Copenhagen

Turku

Szeged

Milan

Napoli

Roma

Chiba

Fukuoka

Hanamaki

Hokkaido

Miyagi

Nagasaki

Osaka

Osaka-Fu

Amsterdam

Seoul

Barcelona

Madrid

Stockholm

Ankara

Izmir

Kocaeli

Birmingham

Liverpool

London